The Drug Eluting Balloon Market size was estimated at USD 1.09 billion in 2024 and expected to reach USD 1.27 billion in 2025, at a CAGR 15.84% to reach USD 2.65 billion by 2030.

The Drug Eluting Balloon (DEB) market focuses on specialized medical devices that release antiproliferative drugs to target areas during angioplasty, particularly in the treatment of cardiovascular diseases such as Peripheral Artery Disease (PAD) and in-stent restenosis. The necessity for DEBs lies in their ability to reduce the risk of restenosis without leaving permanent implants, like stents, which can lead to chronic inflammation. They find application primarily in cardiovascular interventions, showcasing a growing end-use scope in hospitals and specialized cardiac care centers. Market growth is driven by the rising prevalence of cardiovascular diseases, increasing demand for minimally invasive procedures, and technological advancements in drug delivery mechanisms. Opportunities are marked by increasing healthcare expenditures and emerging markets investing in advanced cardiovascular care, where regulatory approvals and cost management strategies can enhance market penetration. However, the market faces limitations including high costs associated with DEB technologies, which can deter widespread adoption in cost-sensitive regions, and stringent regulatory frameworks that can delay market entry and innovation. The high dependency on clinical outcomes for market acceptance remains a critical challenge. Innovation and research can focus on improving drug delivery efficacy, reducing procedure costs, and enhancing patient outcomes through hybrid technologies combining DEBs with imaging techniques for precision targeting. Furthermore, collaborations between technology firms and healthcare providers are crucial to fostering scalable innovations. The nature of the DEB market is competitive and dynamic, with an emphasis on product differentiation and outcome-based marketing strategies. For businesses to thrive, it is essential to invest in comprehensive clinical trials, engage in strategic partnerships for co-development, and focus on expanding their pipeline portfolios to cater to emerging therapeutic areas, thus leveraging the escalating need for effective cardiovascular treatment solutions worldwide.
Ask ResearchAI anything
World's First Innovative Al for Market Research
Market Dynamics
The market dynamics represent an ever-changing landscape of the Drug Eluting Balloon Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
- Market Drivers
- Influence of healthcare infrastructure development on the adoption of drug eluting balloons
- Role of increased funding for research and development in boosting drug eluting balloon innovation
- Impact of increasing prevalence of cardiovascular diseases on drug eluting balloon demand
- Market Restraints
- Identifying comprehensive market restraints that limit the widespread adoption of drug eluting balloons
- Exploring ten critical challenges in the drug eluting balloon industry affecting market growth
- Analyzing the limitations posed by regulatory hurdles in the drug eluting balloon market expansion
- Market Opportunities
- Collaborating with research institutions for innovative developments in drug eluting balloon applications
- Expanding the drug eluting balloon market through partnerships with leading healthcare institutions
- Navigating regulatory landscapes to fast-track drug eluting balloon approvals worldwide
- Market Challenges
- Adapting to rapidly evolving technological advancements within the drug eluting balloon industry
- Addressing issues related to reimbursement models for drug eluting balloons in healthcare systems
- Mitigating supply chain disruptions impacting the availability of drug eluting balloons globally
Market Segmentation Analysis
Type: Significance of coronary DEBs in enhancing deliverability and drug transfer
Coronary drug eluting balloons (DEBs) is an innovative medical device used in percutaneous coronary interventions (PCIs) to treat coronary artery disease. They are carefully designed to deliver anti-proliferative drugs directly to the site of arterial blockage, facilitating the inhibition of neointimal hyperplasia and thus preventing restenosis. Peripheral drug eluting balloons are deployed to treat peripheral artery disease (PAD), particularly in the femoral and popliteal arteries. Similar to their coronary counterparts, these DEBs release medication that helps prevent restenosis by minimizing the growth of the vascular smooth muscle tissue.
Coating Technology: Growing preferences for enduraCoat with better local drug release profile
EnduraCoat technology is a coating designed to provide a uniform and controlled drug transfer to the arterial wall. This technology typically offers a durable, low-dose coating that minimizes particulate loss and ensures a consistent drug release profile. FreePac is a type of coating that combines a synthetic polymer and an antiproliferative drug, ensuring consistent drug transfer and bioavailability. FreePac is typically designed to address the challenges of restenosis in peripheral arterial disease. Paccocath technology incorporates a mixture of a chemotherapeutic drug and a specific excipient encapsulated within a matrix. This matrix coating allows for controlled drug release to the target lesion, preventing neointimal hyperplasia. TransPax is a newer coating technology that uses a bioresorbable carrier for drug delivery. TransPax may be preferred for patients who could benefit from a bioresorbable drug delivery system. This system is potentially advantageous where the long-term presence of non-resorbable polymers can be undesirable.
Porter’s Five Forces Analysis
The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Drug Eluting Balloon Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.
PESTLE Analysis
The PESTLE analysis offers a comprehensive tool for understanding and analyzing the external macro-environmental factors that impact businesses within the Drug Eluting Balloon Market. This framework examines Political, Economic, Social, Technological, Legal, and Environmental factors, providing companies with insights into how these elements influence their operations and strategic decisions. By using PESTLE analysis, businesses can identify potential opportunities and threats in the market, adapt to changes in the external environment, and make informed decisions that align with current and future conditions. This analysis helps companies anticipate shifts in regulation, consumer behavior, technology, and economic conditions, allowing them to better navigate risks and capitalize on emerging trends.
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Drug Eluting Balloon Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Drug Eluting Balloon Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Recent Developments
Advanced NanoTherapies (ANT) Secures USD 4 Million Strategic Investment to Accelerate Clinical Development of SirPlux Duo Drug-Coated Balloon (DCB) for Treating de novo Coronary Artery Disease (CAD)
Advanced NanoTherapies Inc., an innovator in nanotechnology for vascular disease treatment, announced the successful completion of a USD 4 Million Series A funding extension from a reputable yet undisclosed strategic medical device company. This injection of funds is expected to fortify ANT's clinical development activities and expedite its trajectory toward securing U.S. IDE approval for its SirPlux Duo Drug-Coated Balloon (DCB). [Published On: August 22, 2023]
Translumina further Strengthens Its Technology Portfolio with Acquisition of Blue Medical Devices, Netherlands
Translumina recently announced the strategic acquisition of Blue Medical Devices, a pioneer in producing state-of-the-art balloon catheters, including Drug Coated Balloons (DCB), situated in Helmond, Netherlands. With this purchase, Translumina expands its European footprint but also enhances its portfolio of coronary intervention solutions by incorporating Blue Medical's advanced DCB technologies. [Published On: June 29, 2023]
Surmodics Receives FDA Approval for the SurVeil Drug-Coated Balloon
Surmodics, Inc. announced a significant advance with the FDA's approval of its state-of-the-art SurVeil drug-coated balloon (DCB). Specifically designed for treating peripheral artery disease, the SurVeil DCB can now be distributed in the United States for percutaneous transluminal angioplasty procedures on femoral and popliteal arteries. [Published On: June 20, 2023]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Drug Eluting Balloon Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Drug Eluting Balloon Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, B. Braun Melsungen AG, Balton Sp. z o. o., Bayer AG, Becton, Dickinson and Company, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Cardionovum GmbH, Concept Medical, Cook Medical, Inc., Eurocor Tech GmbH, Invamed, iVascular S.L.U., Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Laborie Medical Technologies, Inc., Lepu Medical Technology, M.A. Med Alliance SA by Cordis Corporation, Medtronic PLC, SurModics, Inc., Terumo Corporation, Wellinq, and Zylox-Tonbridge Medical Technology Co., Ltd..
Market Segmentation & Coverage
This research report categorizes the Drug Eluting Balloon Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product Type
- Coronary Drug-Eluting Balloons
- Peripheral Drug-Eluting Balloons
- Application Areas
- Cardiology Applications
- Coronary Artery Disease
- Peripheral Artery Disease
- Nephrology Applications
- Oncology Applications
- Tumor Ablation
- Vascular Tumor Treatment
- Cardiology Applications
- End-User
- Ambulatory Surgical Centers
- Hospitals
- Specialty Clinics
- Material Type
- Composite Material Balloons
- Metal-Based Balloons
- Polymer-Based Balloons
- Drug Type
- Everolimus-Based Balloons
- Paclitaxel-Based Balloons
- Sirolimus-Based Balloons
- Mechanism of Action
- Anti-Proliferative Effects
- Prevention of Restenosis
- Patient Type
- Adult Population
- Geriatric Patients
- Middle-Aged Adults
- Pediatric Population
- Adult Population
- Clinical Trials Phase
- Phase I
- Phase II
- Phase III
- Pricing Category
- Economical Pricing
- Premium Pricing
- Innovation Level
- Advanced Generation
- Generation I
- Generation II
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
This research report offers invaluable insights into various crucial aspects of the Drug Eluting Balloon Market:
- Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
- Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
- Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
- Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
- Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current market size and projected growth?
- Which products, segments, applications, and regions offer promising investment opportunities?
- What are the prevailing technology trends and regulatory frameworks?
- What is the market share and positioning of the leading vendors?
- What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Drug Eluting Balloon Market, by Product Type
- Drug Eluting Balloon Market, by Application Areas
- Drug Eluting Balloon Market, by End-User
- Drug Eluting Balloon Market, by Material Type
- Drug Eluting Balloon Market, by Drug Type
- Drug Eluting Balloon Market, by Mechanism of Action
- Drug Eluting Balloon Market, by Patient Type
- Drug Eluting Balloon Market, by Clinical Trials Phase
- Drug Eluting Balloon Market, by Pricing Category
- Drug Eluting Balloon Market, by Innovation Level
- Americas Drug Eluting Balloon Market
- Asia-Pacific Drug Eluting Balloon Market
- Europe, Middle East & Africa Drug Eluting Balloon Market
- Competitive Landscape
- List of Figures [Total: 37]
- List of Tables [Total: 590 ]
- List of Companies Mentioned [Total: 24]
- How big is the Drug Eluting Balloon Market?
- What is the Drug Eluting Balloon Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?